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Abstract
Neuroprotective agents, including specific hormones, may play a role in preventing
cellular damage following an ischemic event or brain injury. Astrocytes are specialized glial cells
within the central nervous system that play roles in synapse development, blood flow regulation,
extracellular homeostasis, synapse function, energy and metabolism (Sofroniew and Vinters,
2009). Research using astrocytes in cell viability studies can be beneficial in deepening our
understanding of specific neuroprotective effects of various steroid hormones including
progesterone. Progesterone has been shown to have neuroprotective capabilities in the central
nervous system (Scarpin et ah, 2009). Although progesterone shows great therapeutic potential,
effects of the synthetic forms, progestins, including ethynodiol diacetate, are not as well known
(Asi et al., 2016). The purpose of my study was to understand the effects of progestins on glial
cell-derived culture viability and understand how progestins influence the viability of astrocytes
under the treatment of epinephrine. My goal was to determine the degree to which in vitro-
pretreatment of cultured glia with varying concentrations of ethynodiol diacetate affects cell
viability and protects cells from the toxicity of epinephrine. Cells treated with epinephrine had
significantly higher cell viability than untreated cells and treated cells were not significantly
different from untreated controls (2-way ANOVA, F9.3o=4.478, P=0.043). There was no
significant difference in cell viability between concentrations of ethynodiol diacetate (2-way
ANOVA, F9,3o=0.0206, P=0.933). The results of this study suggest that under these treatment
parameters, ethynodiol diacetate does not protect glial-derived cultures from oxidative stress.
These results also show that short-term epinephrine treatment improves cell viability in the
human glioma-derived cell line used in this study.
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Background
Oral contraceptive pills are composed of estrogen and progestagens or progestagens
alone. Progestagens prevent pregnancy using three paths of prevention: (1) inhibition of
ovulation, (2) thickening of cervical mucus to prevent sperm penetration, and (3) changes in
endometrial lining to prevent implantation (Regidor, 2018). Current forms of contraceptives
include combined hormonal contraceptives in the form of pills, patches or vaginal rings, and
progestogen-only contraceptives in the form of pills, injections, implants, or intrauterine devices
(Regidor, 2018). The most frequent side effect of progestogen-only contraceptives is irregular
bleeding, but other side effects include menstrual irregularities, abdominal discomfort, dizziness,
anxiety, asthenia, breast tenderness, mood changes, mild hirsutism, sexual pain, acne, headache,
weight gain, mastalgia, vaginal infections, and deleterious interactions with antibiotics (Regidor,
2018). Progestogen-only contraceptives are recommended for women that are breastfeeding,
smoking, obese, hypertensive, and for women who have a history of heart disease, migraines, and
cancer (Ahrendt et al., 2010).
Under normal circumstances, progesterone is a hormone that prepares the female body for
pregnancy. The term progestogen is used to describe a substance that mimics progesterone by
binding to progesterone receptors (PR) (Carroll et al., 2016). Progestagens include natural
progesterone produced by the ovaries and synthetic progestins that are taken as contraceptives or
hormone replacement therapy (HRT). Synthetic progestins have a different chemical structure
from natural progesterone, but replicate some of the same physiological effects (Asi et al., 2016).
When fertilization occurs, progesterone thickens the uterus lining for implantation and
nourishment of the ovum (Lieberman and Curtis, 2017). Progesterone also causes the mammary
glands to dilate and develop into secretory epithelium (Lieberman and Curtis, 2017). Along with
preparing the body for pregnancy, progesterone prevents further ovulation after an ovum has been
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formed (Sitruk-Ware and El-Etr, 2013). Since progesterone is derived from cholesterol, it is a
hydrophobic substance and does not readily enter the bloodstream when taken orally. Progestins
are synthetic versions of progesterone that have hydrophilic functional groups added to better be
absorbed by the body and into the bloodstream (Berg, 2015). Progestins can be divided into two
classes based on the chemical similarity to either testosterone or progesterone. Progestins, unlike
progesterone, bind to androgen receptors, estrogen receptors, glucocorticoid receptors, and
mineralocorticoid receptors with different affinities. These interactions may be agonistic,
antagonistic, or have no effect (Giatti et al., 2016).
Progesterone and progestins affect the cell by binding to nuclear progesterone receptors
(PR). PR are ligand-activated nuclear transcription regulators which are made up of a central
DNA binding domain and a carboxyl-terminal ligand binding domain (Scarpin et ah, 2009).
These receptors also contain activation and inhibitory functional elements. PR regulates
transcription through genomic and non-genomic pathways. There are two PR isoforms: PRA and
PRB. PRA differs from PRB in that it lacks 164 amino acids at the N-terminus. These isoforms
have been shown to differentially regulate gene transcription, although the mechanism has not
been fully studied. In the mouse, PRB was shown to be necessary for the development of
mammary glands, and PRA was necessary for the development of uterine and reproductive tissues
(Scarpin et al,. 2009). PR proteins are expressed in tissues including the uterus, mammary gland,
brain, pancreas, bone, ovary, testes, and urinary tract (Scarpin et al,. 2009).
Along with progesterone’s role in reproduction, it also has other therapeutic potentials in
the body including the cardiovascular system, bone tissue, and central nervous system (Scarpin et
al., 2009). PRs have been found within many areas of the brain and have been associated with
functions including cognition, neuroprotection, and dendritic remodeling. Specifically,
progesterone has also been shown to reduce epileptic activity and has neuroprotective abilities
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after traumatic or ischemic brain injuries (Sitruk-Ware and El-Etr, 2013). Although progesterone
shows great therapeutic potential, the effect of progestins on the nervous system varies greatly
based on the structure of the progestin. Some progestins, such as segesterone acetate, have been
observed to promote remyelination of neurons by oligodendrocytes, while others such as
medroxyprogesterone acetate did not exhibit the same protective effects (Giatti et al., 2016). Due
to the lack of knowledge of the effects of progestins on the central nervous system, it is necessary
that the effects of progestins on the central nervous system be studied.
Astrocytes are specialized glial cells within the central nervous system (CNS) that
outnumber neurons with a ratio of 5:1. They perform a variety of functions that are critical for the
brain and spinal cord and are found within the entirety of the CNS. Astrocytes play roles in
synapse development, blood flow regulation, extracellular homeostasis, synapse function, energy
and metabolism, and are main components of the blood-brain barrier (Sofroniew and Vinters,
2009). Due to their participation in extracellular metabolism, astrocytes can remove harmful
toxins from the CNS. Astrocyte deficiency or damage has been linked to neurodegenerative
diseases such as Alzheimer's disease and dementia because of the inability to remove these toxins
(Chen et al., 2003). Although astrocytes show neuroprotective capabilities, they have also been
shown to trigger inflammatory responses and increase neuronal apoptosis (Zhang and Jiang,
2015). Research using astrocytes in cell viability studies can deepen our understanding of specific
neuroprotective effects of progestins.
Although progesterone is known to have several neuroprotective properties in the nervous
system, the effects of progestins vary within the system and have not been extensively studied
(Sitruk-Ware and El-Etr, 2013). The purpose of my study was to understand the effects of
progestins on the viability of glial-derived cells and understand how progestins influence the
viability under the stress of epinephrine. The progestin used in this study is ethynodiol diacetate,
             
               
               
             
              
             
              
             
        
which is chemically-related to testosterone (Giatti et al., 2016). Along with having some
androgenic effects, this progestin also exhibits slight estrogenic effects, but its role in the CNS
unknown. My goal was to determine the degree to which in v/tro-pretreatment of cells with
varying concentrations of ethynodiol diacetate affects cell viability and protects cells from the
toxicity of epinephrine. Cells were treated with ethynodiol diacetate, and half of the treatment
groups were stressed using epinephrine. I predicted that the cell viability would decrease
following epinephrine treatment alone as a result of the stress treatment. 1 predicted that
ethynodiol diacetate pretreatment of the cells prior to epinephrine treatment would result in




             
            
             
              
             
                 
               
                 
                
              
                  
                
               
           
   
               
                 
             
               
               
            




Cells used in this research were human cultured glioma-derived glial cells (132INI) purchased
from Sigma Aldrich. These cells demonstrate astrocyte-like functions and properties in culture.
The cell media used was Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, and 1% streptomycin/penicillin in T-75 flasks. The media was
changed every 2-3 days. After the cells propagated to about 70-80% confluency, subculturing
started. A solution of 0.53 mM EDTA and 25% trypsin was added to the flask (2-3 mL).
Complete growth medium was added after the cells had dispersed and was followed by cell
aspiration. The cells were centrifuged to remove excess trypsin and plated in a 96 well plate. Each
well contained 200 pL of media with a concentration of lxl 06 cells/mL. The cell concentration
was determined using a BioRad cell counter. Using equal parts trypan blue and prepared
astrocytes, a solution was made. Next, 10 pL of this 1:1 solution was added to a BioRad cell
counter slide and inserted into the cell counter. Live cell counts were obtained and used for
concentration adjustment to 1 x 106 cells/mL and then added to wells. Treatments started the
following day. Cells were stored at 37°C with 5% supplemented CO2.
Treatment ofCells
Cells in culture were treated with varying concentrations of ethynodiol diacetate (0 M control, 10
nM, 100 nM, 1 pM, 10 pM) (Johnson, 2016). Half of the wells were treated with epinephrine
(200 pM) 60 minutes after ethynodiol diacetate treatment (Smith, 2017). This concentration of
epinephrine was chosen based on a previous study that stated 100 pM epinephrine treatment had
no effect on the cell viability of astrocytes. The author stated that, consistent with previously
published studies, increased concentration of epinephrine should stress the cells (Smith, 2017).
The media was changed one hour after epinephrine addition, and ethynodiol diacetate was added
                
            
 
   
             
   
            
   
                
                    
               
             
            
 
    
             
                
                   
                 
              
            
   
               
              
              
6
to the new media. Viability of the astrocytes was measured after 24 hours. Four trials were
completed of these above treatments. The treatments are outlined in Table 1.
Treatment Progestin Concentration
Ethynodiol Diacetate Control (no progestin) 10 nM 100 nM 1 pM 10 pM
Ethynodiol Diacetate +
Epinephrine Control (no progestin) 10 nM 100 nM 1 pM 10 pM
*Epinephrine: 200 pM
Table 1. 96-well plate diagram for treatment. Cells in the first row were treated with ethynodiol
diacetate in concentrations of 0 M, 10 nM, 100 nM, 1 pM and 10 pM. Cells in the second row
were treated with the same concentrations of ethynodiol diacetate and were also treated with 200
pM epinephrine one hour after initial ethynodiol diacetate treatment. Two hours after initial
ethynodiol diacetate treatment, media was changed and cells were retreated with ethynodiol
diacetate.
MTT Cell Proliferation Assay
Cell viability after treatment was assessed using an MTT Cell Proliferation Assay (Sigma
Aldrich) after 24 hours of treatment. A blank well was included that contained only media with
no cells. To each well, 10 pL of the MTT reagent was added and the cells were incubated for
three hours and 45 minutes or until a blue/purple precipitate formed. Next, 100 pL of the MTT
reagent was added to the wells. The spectrophotometric plate reader was used to measure
absorbance at 570 nm. A high absorbance value indicated high cell proliferation.
Analysis ofdata
Four trials were run. To analyze absorbance values, the blank reading was subtracted from the
treatment readings and a ratio made with the corrected control value. The independent variables
that were measured were ethynodiol diacetate treatments and if astrocytes were stressed or not
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stressed. To evaluate statistical significance between treatments, a 2-Way Analysis of Variance
(ANOVA) and Tukey’s post hoc test was used with a p-value<0.05 indicating significance.
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Results
There was significant increase in the viability of cells treated with epinephrine compared
to untreated cells (Figure 1,2-way ANOVA, F9,30=4.478, P=0.043). There was no significant
difference in astrocyte cell viability between concentrations of ethynodiol diacetate or between
cells treated with ethynodiol diacetate and untreated cells (Figure 1,2-way ANOVA,
F9,3o=0.0206, P=0.933). Cell viability data are reported as the average absorbance in the treatment
well compared to control (+/- standard deviation). The viability ratio of the cells treated with 0 M
ethynodiol diacetate followed by epinephrine treatment was 11.49 (+/- 10.71). The viability ratios
of the cells treated with 0.01 pM ethynodiol diacetate were 3.82 (+/- 3.94) and 4.67 (+/- 4.54) for
the cells untreated with epinephrine and cells that were treated with epinephrine, respectively.
The viability ratios of the cells treated with 0.1 pM ethynodiol diacetate were 3.37 (+/- 1.88) and
5.94 (+/- 8.11) for the cells untreated with epinephrine and cells that were treated with
epinephrine, respectively. The viability ratios of the cells treated with 1 pM ethynodiol diacetate
were 3.01 (+/- 1.88) and 6.28 (+/- 4.76) for the cells untreated with epinephrine and cells that
were treated with epinephrine, respectively. The viability ratios of the cells treated with 10 pM
ethynodiol diacetate were 3.75 (+/- 3.65) and 4.44 (+/- 5.00) for the cells untreated with
epinephrine and cells that were treated with epinephrine, respectively. Figure 1 shows the average
viability ratios compared to control (+/- 1 S.D.) of stressed with epinephrine or unstressed, treated
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Concentration of Ethynodiol Diacetate (fjM)
Figure 1. Average astrocyte viability (+/-1 S.D.) for cells stressed or unstressed when treated with varying
concentrations of ethynodiol diacetate. There was no significant difference in astrocyte viability between
varying concentrations of ethynodiol diacetate (2-way ANOVA, F9,3o=0.0206, P=0.933). There was
significant increase in glial cell viability (+/-1 S.D.) between cells that were treated with epinephrine
versus the untreated cells (2-way ANOVA, F9,30=4.478, P=0.043).
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Discussion
There was no significant difference in glial cell viability between ethynodiol diacetate
treatment groups. There was a significant difference in cell viability between cells that were
stressed with epinephrine and cells that were left unstressed. Cells stressed with epinephrine had
increased cell viability than cells that were left unstressed, indicating that epinephrine did not
effectively stress the astrocytes and in fact gave the cells a survivability advantage. In previous
studies, it was shown that cells derived from cancer cell lines had increased cell viability when
treated with epinephrine (Pu J et ah, 2012). The cell line used in this study is derived from glioma
tissue, which is a cancerous tissue. Thus, this result is consistent with those studies. In future
studies, epinephrine should not be used as a stressor for this cell line due to its inability to
decrease cell viability
In future studies, oxidative stress could be measured with flow cytometry to understand if
the cells were oxidatively stressed effectively. Viable aerobic cells produce reactive oxygen
species such as O2", OH, and peroxides but the cells also have an antioxidant defense system to
reduce an excessive concentration of these reactive oxygen species (Eruslanov and Kusmartsev,
2010). In cells that are oxidatively stressed, the antioxidant defense mechanism is incapable of
decreasing the ROS concentration because it is too high. Flow cytometry uses 2'-7'-
Dichlorodihydrofluorescein diacetate (DCFH-DA) as a intracellular probe to measure oxidative
stress. DCFH-DA is non-fluorescent and is oxidatively converted to 2'-7'-dichlorofluorescein
(DCF) which fluorescence at 530 nm (Eruslanov and Kusmartsev, 2010). The fluorescence of
DCF measured at 530 nm with a flow cytometer is assumed to correlate with the concentration of
hydrogen peroxide within the cell. High hydrogen peroxide concentration indicates high oxidative
stress for the cell (Eruslanov and Kusmartsev, 2010). The oxidative stress for the epinephrine-
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treated glial cells should be measured and if the cells are being oxidatively stressed, the cell
viability increase would not be contributed to the lack of oxidative stress on the cells.
Trials performed had very different results, which can be seen from the large error bars in
Figure 1. When performing the trials, it was noted that cells did not appear to be adhered to the
bottom of the 96-well plate when treatment started. The cells formed disks and when adding
solution or removing solution, the disks moved around in the media. Thus, when the media was
removed viable cells and nonviable cells could have been removed. If the viable cells were
removed, the results could be skewed. These observations could indicate the cells were not
healthy prior to treatments or that they needed to be given more time to adhere in the 96-well
plate. In future trials the cells should be left in the 96-well plates longer in order to become more
established in the wells to avoid removing healthy cells.
From these results, ethynodiol diacetate, similarly to medroxyprogesterone acetate, does
not appear to have protective capabilities previously seen in progesterone and segesterone acetate
(Sitruk-Ware and El-Etr, 2013, Giatti et ah, 2016). Ethynodiol diacetate is more structurally
similar to testosterone, while segesterone acetate and medroxyprogesterone acetate are derivatives
of progesterone (Giatti et ah, 2016). These structural differences could perform different tasks
within the body and may explain why segesterone acetate has protective capabilities, whilst
ethynodiol diacetate does not. These differences, however, would not explain why
medroxyprogesterone acetate does not have protective capabilities and segesterone acetate does,
considering that both hormones are progesterone-derived. Further studies should explore trends in
neuroprotective capabilities in testosterone related progestins and progesterone related
progestogens and the mechanisms the hormones influence.
These treatments should be repeated to produce more consistent results to better assess to
neuroprotective effects of ethynodiol diacetate. Further studies should be performed with a more
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effective stressor and with cells more firmly adhered to the 96- well plate. Future work should
also investigate the interactions between epinephrine and ethynodiol diacetate to better
understand if they negatively regulate each other. Additionally, further studies could explore an
increase in ethynodiol diacetate concentration to better understand if the hormone has
neuroprotective effects at higher concentrations.
Ethynodiol diacetate is one of the main components of many oral birth control pills (Asi et
ah, 2016). The effects that ethynodiol diacetate have on the central nervous system are still
unclear. The impact that ethynodiol acetate has on the central nervous system should be studied
more extensively because many women use hormonal birth control over a period of decades.
Negative effects that occur over many years could be a contributing factor to many
neurodegenerative diseases, such as Alzheimer’s, but positive effects over many years may
protect against these diseases. For this reason, more studies need to be completed on the effects of
progestogens on the central nervous system.
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